- Recommendation ID
- NG122/01
- Question
What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell lung cancer following multimodality treatment including surgery?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made the recommendation for research, see the rationale on management of operable stage IIIA–N2 non-small-cell lung cancer .
Full details of the evidence and the committee's discussion are in evidence review C: Management of NSCLC stage IIIA-N2.
Source guidance details
- Comes from guidance
- Lung cancer: diagnosis and management
- Number
- NG122
- Date issued
- March 2019
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/09/2023 |